New York State ID/DD Nurses Association

WHAT's NEW

Learn about what's new in nursing.

What's New From The State

Plans for the 2019 State Conference are in full swing. The committee always welcomes input from members. Have you heard a speaker who is a good presenter and has a general interest topic. Even if if wasn't able to be a part of 2019 agenda, it could be for next year.  Part of the Association Strategic Plan is to broaden the number of members who are involved in the executive board and standing committees. This is moving forward and it is good to see new faces and hear new ideas at board meetings. A goal is to find new ways to help our membership work effectively. 

What's New From The Zones?

Please send in your memberships to support your zone and state organization. Reach out to those who may not be aware of our organization and the benefit of networking with other ID/DD nurses. Membership dues need to be received in order to get the member rate for conference.

What's New From OPWDD?

PONs continue to be the standard that reviewers are looking for to see if dsp's are aware of how to provide the appropriate care. Simple, easy to understand information and directives are best. Avoid long, drawn out medical background information that won't be read by staff.

What's New From Our Members?

Thank you to Fred Wetzel for sending this: Shortage of APLISOL® The Centers for Disease Control and Prevention (CDC) is expecting a 3 to 10 month nationwide shortage of APLISOL®, a product of Par Pharmaceuticals. APLISOL® is one of two purified-protein derivative (PPD) tuberculin antigens that are licensed by the United States Food and Drug Administration (FDA) for use in performing tuberculin skin tests. The manufacturer notified CDC that they anticipate a supply interruption of APLISOL® 5 mL (50 tests) beginning in June 2019, followed by a supply interruption of APLISOL® 1 mL (10 tests) in November 2019. The expected shortage of APLISOL® 1 mL (10 tests) could occur before November 2019, if demand increases before then. The 3-10 month timeframe for the nationwide shortage is the manufacturer’s current estimate and is subject to change. To monitor the status of this supply interruption, visit FDA’s “Center for Biologics Evaluation and Research (CBER)-Regulated Products: Current Shortages” webpage. BackgroundTwo types of immunological methods are used for detecting Mycobacterium tuberculosis infection: tuberculin skin tests (TSTs) and interferon-gamma release assay (IGRA) blood tests. TSTs and IGRAs are used for diagnosing latent TB infection and may aid in diagnosing TB disease. Additional evaluation and testing is necessary to distinguish between latent TB infection and TB disease, and to determine the correct treatment. When findings, such as chest radiography and mycobacterial cultures, are sufficient for confirming or excluding the TB diagnosis, the results from a TST or an IGRA blood test might not be needed. Most TB cases in the United States are diagnosed with a set of findings including results from one of these tests. Two FDA-approved PPD tuberculin antigens are available in the United States for use in performing TSTs: TUBERSOL® and APLISOL®. In controlled studies, the concordance between the two products is high. When TB disease is strongly suspected, specific treatment should be started regardless of results from TST or an IGRA blood test. RecommendationsCDC recommends three general approaches to prevent a decrease in TB testing capability because of the expected shortage of APLISOL®. Substitute IGRA blood tests for TSTs. Clinicians who use the IGRA blood tests should be aware that the criteria

What's New From In The News?

The once fatal disease of HIV is now considered treatable. The gap in life expectancy between those without HIV and those with that diagnosis has decreased from 44 years less life expectancy to 12 years less, individuals with HIV still face many health challenges. Currently 3/4 of people living with HIV are over 45. As their age increases so does their risk of heart and blood vessel conditions. More study needs to be done on these health factors. Medpage

facebook